Abiomed, Inc. (ABMD) Tops Q2 Views; Reaffirms FY12 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Financial Fact:
Selling, general and administrative: 53.09M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Selling, general and administrative: 53.09M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Abiomed, Inc. (NASDAQ: ABMD) reported Q2 EPS of $0.09, $0.18 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $29.5 million versus the consensus estimate of $27.7 million.
The stock was halted to report the results.
The stock was halted to report the results.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- SmartRent (SMRT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, Guidance, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
